CANnabinoids for Drug Resistant Epilepsy (DRE) in Adults and Children (NCT07023744) | Clinical Trial Compass
Not Yet RecruitingPhase 2
CANnabinoids for Drug Resistant Epilepsy (DRE) in Adults and Children
90 participantsStarted 2025-10-01
Plain-language summary
Epilepsy is a neurological disorder affecting more than 50 million people globally, including more than 260,000 Canadians. Cannabidiol (CBD) reduces seizure frequency and improves quality of life for adults and children with Drug Resistant Epilepsy (DRE). Several uncontrolled, small, open label studies reported that CBD-enriched Cannabis Herbal Extract (CHE) resulted in a reduction of seizure frequency, but we lack critical information on efficacy, comparative effectiveness and dosing of CBD and ∆9-tetrahydrocannabinol (THC) in children and adults with DRE. CAN-DRE is an early phase, triple-blind, placebo-controlled, randomized clinical trial to answer the questions of if cannabinoids work to reduce seizures in children and adults (24 months to 55 years) with DRE and if CBD works better in an isolate or in a CBD-enriched Cannabis Herbal Extract. The primary outcome of CAN-DRE is reported monthly seizure count from baseline to maintenance phase.
Who can participate
Age range24 Months – 55 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Ages 24 months to 55 years old at the time of enrollment
✓. Diagnosed with DRE: not achieved seizure freedom, with adequate trials of 2 antiseizure medications 29
✓. Medical history of 4 + clinically recognizable seizures (any type with clusters counted as a single event) per month
✓. Have a negative pregnancy test at screening for patients who have experienced menarche
✓. Agree to abstain from driving and recreational cannabis use throughout the study
Exclusion criteria
✕. Diagnosis of psychogenic non-epileptic seizure
✕. Recent (\<30 days) change in anticonvulsant therapies including anticonvulsant medications, or settings on vagal nerve stimulator
✕. Ketogenic diet started within 6 months (participants stable on the ketogenic diet for more than 6 months are eligible to participate)
✕. Vagal nerve stimulator implanted and activated within 12 months